Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
S
Shmuel Yaccoby
High Impact
Professor
Also affiliated: St. Luke's-Roosevelt Hospital Center (2001); Howard Hughes Medical Institute (2001); Norwegian University of Science and Technology (2000); Cornell University (2001); University of Arkansas Medical Center (2004–2015); Cancer Research And Biostatistics (2006–2015); Weill Cornell Medicine (2001); AbbVie Biotherapeutics (United States) (2009); Rockefeller University (2001)
Internal Med, College of Medicine
46 h-index
197 pubs
8,239 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Shmuel Yaccoby's research program focuses on multiple myeloma, a hematologic malignancy. His work investigates the intricate interactions between myeloma cells and the bone marrow microenvironment, particularly the mechanisms that lead to bone destruction and tumor progression. Yaccoby has studied how myeloma influences osteoclast differentiation and activity, impacting bone metabolism and disease advancement.
His laboratory has explored potential therapeutic strategies, including antibody-based inhibition of key signaling molecules like DKK1 to suppress tumor-induced bone resorption. Yaccoby has also contributed to understanding the molecular classification of multiple myeloma and has investigated imaging techniques such as MRI and FDG-PET for diagnostic and clinical applications. He has developed and utilized animal models, including SCID-hu mice, to study the biology of myeloma and its manifestations, facilitating research into treatment responses and disease mechanisms.
Metrics
- h-index: 46
- Publications: 197
- Citations: 8,239
Positions
-
Professor publications 1998–2025University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
-
University of Arkansas for Medical Sciences publications 1998–2025ORCID
Selected Publications
-
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice (2025)
-
Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma‐induced bone disease (2025)
-
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression (2023)
-
Growth and dormancy control of myeloma cells by mesenchymal stem cells (2023)
-
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers (2021)
-
PHF19 inhibition as a therapeutic target in multiple myeloma (2021)
-
CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction (2020)
-
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers (2020)
-
The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma (2019)
-
The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells (2019)
-
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma (2019)
-
Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma (2019)
-
Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes (2018)
-
Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors (2018)
-
Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes (2018)
Grants & Funding
As listed on this researcher's institutional profile.
- Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice ZymoGenetics, Inc Principal Investigator
- Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma Millennium Pharmaceuticals, Inc. Principal Investigator
- Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo Abbott, Inc. Principal Investigator
- DEAP Awards - S Yaccoby - UAMS VCRI - FY26 UAMS Division of Research and Innovation Principal Investigator
- Anti-myeloma efficacy of PDACs/HPP Celgene Principal Investigator
- Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo BioInvent Principal Investigator
- Role of SPRPs in the anti-myeloma response of osteoblasts Multiple Myeloma Research Foundation Principal Investigator
- Study of Effect of VELCADE on Osteoblast Activity Millennium Pharmaceuticals, Inc. Principal Investigator
- Anti-myeloma efficacy of PT-100 and PT-630 in ex vivo and in vivo systems for primary myeloma Point Therapeutics, Inc Principal Investigator
- Effect of antiCD56-cytotoxic drug conjugate on myeloma cell growth in the bone marrow microenvironment ex vivo and in vivo ImmunoGen, Inc. Principal Investigator
- Potentiating Natural Killer Cell Anti-Myeloma Effects NIH Co-Investigator
- Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma Vantia Therapeutics Ltd. Principal Investigator
- Role of novel myeloma subpopulations in the disease progression and drug resistance US Department of Defense Principal Investigator
- Targeting Dkk1 in multiple myeloma with humanized andti-DKk1 neutralizing antibody Multiple Myeloma Research Foundation Principal Investigator
- Myeloma-Microenvironment Interaction Dynamics NIH Principal Investigator
Collaboration Network
Top Collaborators
Bart Barlogie
University of Arkansas for Medical Sciences
105 shared publications
In database
- The molecular classification of multiple myeloma
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
- Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
Showing 5 of 105 shared publications
Joshua Epstein
Winthrop Rockefeller Foundation (US)
84 shared publications
- The molecular classification of multiple myeloma
- Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
- Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
Showing 5 of 84 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
63 shared publications
In database
- The molecular classification of multiple myeloma
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Showing 5 of 63 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
51 shared publications
In database
- The molecular classification of multiple myeloma
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
- Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
Showing 5 of 51 shared publications
Wen Ling
Winthrop Rockefeller Foundation
50 shared publications
In database
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
Showing 5 of 50 shared publications
John D. Shaughnessy
Winthrop Rockefeller Foundation
47 shared publications
In database
- The molecular classification of multiple myeloma
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Showing 5 of 47 shared publications
Xin Li
University of Arkansas for Medical Sciences (US)
35 shared publications
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- Role of decorin in the antimyeloma effects of osteoblasts
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Showing 5 of 35 shared publications
Sharmin Khan
University of Arkansas for Medical Sciences
33 shared publications
In database
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Showing 5 of 33 shared publications
Gareth J. Morgan
NYU Langone Health (US)
33 shared publications
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Showing 5 of 33 shared publications
Angela Pennisi
University of Arkansas for Medical Sciences (US)
25 shared publications
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- Role of decorin in the antimyeloma effects of osteoblasts
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
- Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
- Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone
Showing 5 of 25 shared publications
Antje Hoering
Cancer Research And Biostatistics (US)
25 shared publications
- Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
Showing 5 of 25 shared publications
Faith E. Davies
University of Arkansas for Medical Sciences (US)
24 shared publications
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma
Showing 5 of 24 shared publications
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
24 shared publications
In database
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
Showing 5 of 24 shared publications
Sadie Johnson
Winthrop Rockefeller Foundation (US)
23 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
Showing 5 of 23 shared publications
Carolina Schinke
Winthrop Rockefeller Foundation
23 shared publications
In database
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
Showing 5 of 23 shared publications
Similar Researchers
Based on overlapping research topics
Silvia Marino
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Janet L. Lukacs
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Medical Imaging Techniques and Applications
Alexandra Gutierrez Vega
University of Arkansas at Fayetteville
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Disease Models, Animal
Sharmin Khan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Bone Metabolism and Diseases
Cancer Cells and Metastasis
Shanique Murray
University of Arkansas at Fayetteville
Cancer Cells and Metastasis
Disease Models, Animal
Cancer-related molecular mechanisms research
Charles P. Mercado
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Cancer-related molecular mechanisms research